Anti-Neprilysin is an enzyme, commonly known as neutral endopeptidase which is involved in degradation of various peptides and plays a vital role in blood pressure regulation and fluid homeostasis. Anti-Neprilysin drugs are used for treatment of heart failure. Heart failure occurs when heart muscle does not pump blood efficiently leading to fluid accumulation in the lungs and other parts of the body.
The global Anti-Neprilysin Market is estimated to be valued at US$ 1,263.3 Mn in 2023 and is expected to exhibit a CAGR of 4.6% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Market key trends:
The increasing prevalence of heart failure across the globe is the major factor fueling the growth of anti-neprilysin market. As per American Heart Association’s Heart Disease and Stroke Statistics report, more than 6 million Americans suffer from heart failure and about half of people who develop heart failure die within 5 years of diagnosis. Moreover, heart failure incidence and prevalence is rising globally due to increasing aged population, growing risk factors such as obesity, diabetes, and cardiovascular diseases. As anti-neprilysin drugs are majorly used for treatment of heart failure, rising prevalence of the disease is expected to surge the demand for these drugs during the forecast period.
Strength: The anti-neprilysin market offers lucrative growth opportunities owing to the increasing prevalence of heart failure. The drug is effective in reducing cardiovascular deaths.
Weakness: High costs associated with R&D for new drugs and clinical trials pose significant challenges. Side effects of existing drugs limit their use.
Opportunity: Growth in geriatric population susceptible to heart diseases will drive demand. Ongoing research aims to develop safer and more effective neprilysin inhibitors.
Threats: Patent expiries of blockbuster drugs enable entry of generics, impacting revenues of established players. Stringent regulations for approvals delay market entry of new products.
The global anti-neprilysin market is expected to witness high growth over the forecast period. North America currently dominates the market contributed to growing prevalence of heart diseases. Increasing healthcare expenditure and availability of advanced treatments are supporting market growth in the region.
Asia Pacific is poised to witness fastest growth owing to rising elderly population, growing awareness about heart diseases, and increasing healthcare spending in countries such as China and India. Players are exploring opportunities in Asia Pacific to benefit from unmet needs.
Key players operating in the anti-neprilysin market are BIOPROJET, Novartis AG, Pharmaleads SA, Theravance Biopharm, Cipla Inc, and Oceanic Pharmachem Pvt. Ltd. These companies are focusing on strengthening their product portfolio through partnerships, mergers, acquisitions, and collaborations to gain market share. Ongoing clinical trials aim to establish efficacy and safety of new neprilysin inhibitors for indications like heart failure and hypertension.
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it